Clinical trials: Overweight, Obesity
Obesity, Type 2 Diabetes
MagDI Canada Study
The objective of the MagDI Canada study is to evaluate the performance and safety of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial…
- Trial name
- NCT06467955
- Testing
- Magnet System, DI Biofragmentable
- Where
- 3 sites in Canada
- Volunteers
- 60 people
- Sponsor
- GT Metabolic Solutions, Inc.
Overweight and Obesity
Phase Ib Clinical Study of HDM1005 Injection
This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation study in overweight or obese subjects to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD)…
- Trial name
- NCT06637020
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity, Morbid, Bariatric Surgery Candidate
Health-connected Devices and Physical Activity Recovery in Bariatric Surgery Patients
The goal of clinical trial is to evaluate the impact of use of health-connected devices and of an Internet-based Intensive follow-up on physical activity recovery during the 6-month period after bariatric surgery in obese…
- Trial name
- MYGOODTRIP (NCT02716480)
- Testing
- Mobility coaching, Diet coaching
- Where
- France
- Volunteers
- 90 people
- Sponsor
- My Goodlife SAS
Overweight or Obese Participants Without Diabetes
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes
To evaluate the efficacy of BGM0504 tablets compared with placebo in reducing body weight in overweight or obese participants without diabetes after 20 weeks of treatment.
- Trial name
- NCT07658560
- Testing
- BGM0504 tablets
- Where
- China
- Volunteers
- 200 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obese
Pharmacodynamics and Pharmacokinetics of Different Glucose Bead Formulations in Obese Healthy Subjects
The goal of this clinical study was to assess pharmacodynamics (PD) and pharmacokinetics (PK) of different Glucose beads formulations in obese healthy subjects under fasting condition. The study was designed in 2 parts.
- Trial name
- NCT05737927
- Testing
- Glucose 8 g coated beads (47% w/w), Glucose 12 g coated beads (47% w/w), Glucose 16 g coated beads (47% w/w)
- Where
- Romania
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Aphaia Pharma US LLC
Adiposity
Study on the Performance of Symmcora® Mid-term Suture Versus Novosyn® Suture in Patients Undergoing Robotic Assisted Gastric Bypass Surgery
The study is designed as a prospective, mono-centric, randomized, patient blinded comparison of unidirectional barbed suture (Symmcora® mid term, UBS) vs. a conventional suture (Novosyn®, CS).
- Trial name
- BARGASTRO (NCT05433688)
- Testing
- Robotic assisted gastric bypass surgery
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Aesculap AG
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Cardiovascular Disease
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors.
- Trial name
- CRESCENDO (NCT00263042)
- Testing
- Rimonabant
- Where
- 43 sites in United States, Argentina and 41 more
- Volunteers
- 18,695 people
- Sponsor
- Sanofi
Obesity
Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients
The primary objective of this study is to assess the effect of rimonabant on the energy intake (kcal/day/meal) from ad-libitum high-fat dinner (primary endpoint), pre- and post-ingestive responses, and the hedonic evaluation of…
- Trial name
- REBA (NCT00481923)
- Testing
- rimonabant (SR141716)
- Where
- United Kingdom
- Volunteers
- 156 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
This study represents the first administration of GSK376501 in humans and the goal is to evaluate its initial safety and tolerability. The way the human body processes GSK376501 will also be determined.
- Trial name
- NCT00404963
- Testing
- GSK376501
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obese, Healthy
The Safety, Tolerability and Pharmacokinetic Study of RAY1225
This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225
- Trial name
- NCT05835752
- Testing
- RAY1225
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Obesity
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors.
- Trial name
- NCT06780449
- Testing
- Cagrilintide, Semaglutide
- Where
- 36 sites in United States, Belgium and 4 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight, Type 2 Diabetes
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
- Trial name
- NCT07539415
- Testing
- DWRX5003, DWC202502, DWC202503
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Obesity
Endostapler Sleeve Gastrectomy Study
The goal of this prospective, post-market study is to measure AEON™ Endostapler performance for laparoscopic sleeve gastrectomy surgery versus the Endo GIA™ Reloads with Tri-Staple™ Technology from Medtronic.
- Trial name
- NCT04617574
- Testing
- AEON Endostapler, Endo GIA Reloads with Tri-Staple Technology
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Lexington Medical Inc.
Obesity, Overweight
A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being…
- Trial name
- NCT07566390
- Testing
- NNC0113-5840
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Obesity, Non-morbid
METHOD (Minimally Invasive, Endoscopically-delivered, Tolerable by Human Individuals, Non-morbid Obesity Device) Study
This will be an open label, single-center, feasibility study comprised of two sequential cohorts( cohort 1: 2 participants; cohort 2: 8 participants).
- Trial name
- SENSATE (NCT00753350)
- Testing
- Sensate™ anchored gastric device
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Sensate LLC
Chronic Respiratory Failure With Hypercapnia, Chronic Obstructive Pulmonary Disease (COPD)
Study Evaluating Telemonitoring and Experimentation in Telemedicine for the Improvement of Healthcare Pathways (ETAPES Program) Compared to Standard of Care in Patients With Chronic Respiratory Failure Receiving Non-invasive Home Ventilation
The ETAPES Program, a French national Experimentation in Telemedicine for the Improvement of Healthcare Pathways, was launched in 2018 for 4 years.
- Conditions
- Chronic Respiratory Failure With Hypercapnia, Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS)
- Trial name
- e-VENT (NCT04615078)
- Testing
- ETAPES Program
- Where
- 11 sites in France
- Volunteers
- 56 people
- Sponsor
- Air Liquide Santé International
Obesity, Obese
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.
- Trial name
- NCT07219589
- Testing
- HM17321
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Obesity
Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones
The study is designed to assess whether repeated dosing with CE-326,597 will cause patients with asymptomatic gallstones (as detected on screening abdominal ultrasound) to become symptomatic.
- Trial name
- NCT00576589
- Testing
- CE-326,597
- Where
- 12 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes, Obesity
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of…
- Conditions
- Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
- Trial name
- TRIUMPH-2 (NCT05929079)
- Testing
- Retatrutide
- Where
- 98 sites in United States, Argentina and 6 more
- Volunteers
- 1,152 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.